Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Abstract Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits
Today, the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies including Hims & Hers and other compounding pharmacies as similar alternatives to FDA-approved drugs
The honest summary is that the country may soon get a cleaner supply of compounds nobody can say much about yet.
However, retatrutide is still being studied, and its long-term safety and tolerability are not as well known as tirzepatide
:max_bytes(150000):strip_icc()/GettyImages-1393991964-5452e32871e7431493115521bb14ae22.jpg)
